Skip to content Skip to footer
Subscribe Now

NEWS

Neurocrine’s Crenessity (Crinecerfont) Secures the US FDA’s Approval to Treat Adults and Pediatrics with Congenital Adrenal Hyperplasia (CAH)
Shots: The US FDA’s approval of Crenessity as an adjunctive treatment to glucocorticoid replacement to treat CAH was based on a global P-III (CAHtalyst Pediatric: n=103, age: 4-17yrs. & Adult: n=182, age: 18-58yrs.) trials. It has also received PRV on approval Pediatric study achieved its 1 & 2EP, depicting ~4x greater reductions in androstenedione…
January 14, 2025
GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio
Shots: GSK to acquire IDRx incl. its lead candidate IDRX-42, for $1B upfront & ~$150M in regulatory milestones (total ~$1.15B). It will also pay success-based milestones & tiered royalties to Merck KGaA for IDRX-42 IDRX-42 (TKI, small molecule) targets key KIT mutations, responsible for proliferation & survival of tumor cells, & is under P-I/Ib…
January 13, 2025
Gilead and LEO Pharma Join Forces to Develop STAT6 Program for Multiple Inflammatory Disorders
Shots: Gilead has entered into a strategic collaboration with LEO Pharma to develop the latter’s small molecule oral STAT6 programs targeting various inflammatory disorders As per the terms, Gilead secures worldwide rights to develop, manufacture & commercialize LEO’s preclinical STAT6 inhibitors & degrading proteins, with LEO having the option to co-commercialize them for dermatology…
January 13, 2025
J&J
Johnson & Johnson’s Reports the CE Mark Approval for Dual Energy Thermocool Smarttouch SF Catheter for Cardiac Arrhythmias
Shots: The CE mark of Thermocool Smarttouch SF Catheter for cardiac arrhythmias was based on SmartfIRE trial in European patients with refractory PAF that depicted 100% acute success rate & first-pass isolation achievement in 96.8% of veins (published in Apr 2024). The Trupulse Generator hardware compatibility is anticipated in H1’25 The company has concluded…
January 13, 2025
Merus and Biohaven Join Forces to Advance Three Bispecific ADC Programs
Shots: Biohaven & Merus have entered into a research collaboration & license agreement to co-develop bispecific ADCs using the former’s ADC conjugation & payload platform plus Merus’ Biclonics tech platform As per the terms, Biohaven will develop preclinical ADCs for 3 Merus’ BsAbs (2 developed via Biclonics & 1 in preclinical) & each is…
January 13, 2025
Veralox Therapeutics to Acquire Nudge Therapeutics, Expanding its Portfolio
Shots: Veralox has signed an exclusive agreement to acquire Nudge Therapeutics & its preclinical cyclic AMP-GMP (cGAS) inhibitors. The financial terms were undisclosed As per the terms, Veralox will resume the development of acquired candidates & initiate acquisition upon achievement of downstream milestones In addition, Veralox is developing VLX-1005 (12-LOX inhibitor) for thrombosis linked…
January 10, 2025
Astellas
Astellas Reports the Health Canada’s Approval of Vyloy (Zolbetuximab) Plus Chemotherapy for Advanced G/GEJ Cancer
Shots: The Health Canada has approved Vyloy + fluoropyrimidine & Pt-based CT as a 1L treatment of locally advanced unresectable or metastatic CLDN 18.2+/HER2-ve G/GEJ adenocarcinoma, with further submissions under review. In addition, Canada’s Drug Agency (CDA-AMC) recommended reimbursement of Vyloy with conditions Approval was based on the P-III (SPOTLIGHT: n= 565 & GLOW:…
January 10, 2025
Load more